The composition spectrum of intestinal bacterial diversity in Chinese pancreatic cancer patients: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

XIE Yangfan ¹ , CAO Lingmin ² , WANG Xueyuan ¹ , LIN Chuan ³ ,  HUANG Hairong ¹

1. Department of Epidemiology, School of Public Health, Hainan Medical University, Haikou 571199, P. R. China;
2. Guangyuan Lizhou District Center for Disease Control and Prevention, Guangyuan 628000, P. R. China;
3. The Library of Hainan Medical College, Haikou 571199, P. R. China;

Corresponding author：

HUANG Hairong, Email: 474938175@qq.com

Keywords：

Pancreatic cancer; Gut microbiota; Diversity composition; Systematic review; Meta-analysis; Cross-sectional study

DOI：

10.7507/1672-2531.202208011

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the intestinal flora diversity profile of pancreatic cancer patients. Methods The Cochrane Library, PubMed, Web of Science, EMbase, CNKI, CBM, WanFang Data and VIP databases were electronically searched to collect cross-sectional studies on the intestinal flora diversity profile of pancreatic cancer patients from inception to December 31, 2021. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies; then, meta-analysis was performed by using RevMan 5.3 software. Results A total of 7 cross-sectional studies involving 250 pancreatic cancer patients and 166 healthy controls were included. The results of meta-analysis showed that: compared with the healthy control group, the intestinal flora of patients with pancreatic cancer α reduced diversity with the Shannon index. High-throughput sequencing found that Proteobacteria and Prevotella were more abundant in pancreatic cancer patients, Firmicutes, Faecalbacterium, Bifidobacterium and Clostridium in pancreatic cancer patients was lower. Conclusion Current evidence shows that the intestinal flora of pancreatic cancer patients has certain characteristics. Proteobacteria and Prevotella are relatively abundant in pancreatic cancer patients. Due to limited quality and quantity of the included studies, more high-quality studies are needed to verify above conclusion.

Citation： XIE Yangfan, CAO Lingmin, WANG Xueyuan, LIN Chuan, HUANG Hairong. The composition spectrum of intestinal bacterial diversity in Chinese pancreatic cancer patients: a systematic review. Chinese Journal of Evidence-Based Medicine, 2023, 23(2): 186-190. doi: 10.7507/1672-2531.202208011 Copy

1.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2.	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin, 2020, 70(1): 7-30.
3.	Sun ZX, Shen YM, Sun ZK, et al. Survival analysis of 198 patients with pancreatic cancer in Hainan, China: A multi-institution prospective study. Asian Pac J Trop Med, 2019, 12(14): 1-13.
4.	朱鑫哲, 李浩, 徐华祥, 等. 2021年胰腺癌研究及诊疗新进展. 中国癌症杂志, 2022, 32(1): 1-12.
5.	赵思涵, 郑健. 胰腺癌病因及发病机制研究进展. 中国癌症防治杂志, 2022, 14(3): 253-263.
6.	中华医学会外科学分会胰腺外科学组. 中国胰腺癌诊治指南(2021). 中华外科杂志, 2021, 59(7): 561-577.
7.	吴白骏, 胡朝全. 胰腺癌免疫治疗的现状与进展. 实用临床医药杂志, 2022, 26(13): 134-138, 144.
8.	侯志颖. 胰腺癌危险因素及其肠道菌群多样性研究. 海口: 海南医学院, 2020.
9.	陈恬. 基于微生物组学的胰腺癌患者口腔及肠道菌群研究. 上海: 海军军医大学, 2020.
10.	Flint HJ, Scott KP, Louis P, et al. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol, 2012, 9(10): 577-589.
11.	田智敏. 参苓白术散对胰腺癌营养状况的改善及胰腺癌与肠道菌群和免疫的关系研究. 上海: 上海中医药大学, 2019.
12.	邓寒丹, 范兴丽. 肠道菌群在肿瘤发生发展及免疫治疗中作用的研究进展. 生物工程学报, 2022, 38(6): 2105-2119.
13.	涂希晨. 胰腺癌患者肠道微环境的研究. 长沙: 湖南师范大学, 2020.
14.	Ren Z, Jiang J, Xie H, et al. Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget, 2017, 8(56): 95176-95191.
15.	Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov, 2018, 8(4): 403-416.
16.	曾宪涛, 刘慧, 陈曦, 等. Meta分析系列之四: 观察性研究的质量评价工具. 中国循证心血管医学杂志, 2012, 4(4): 297-299.
17.	陈卓, 钱祥, 张爱琴, 等. 基于肠道菌群结构特征研究胰腺癌不同中医证型与预后的相关性. 浙江中西医结合杂志, 2019, 29(12): 965-969.
18.	张德, 周文丽, 王雷, 等. 女性胰腺癌患者肠道菌群变化分析. 解放军医学院学报, 2019, 40(11): 1087-1092, 1109.
19.	谢国群, 张院辉, 郭晓冬, 等. 基于高通量测序技术的胰腺癌湿热证患者肠道菌群结构差异与功能变异研究. 上海中医药杂志, 2019, 53(12): 9-16.
20.	Zhou W, Zhang D, Li Z, et al. The fecal microbiota of patients with pancreatic ductal adenocarcinoma and autoimmune pancreatitis characterized by metagenomic sequencing. J Transl Med, 2021, 19(1): 215.
21.	Wang X, Sun Z, Makale EC, et al. Gut microbial profile in patients with pancreatic cancer. Jundishapur J Microbiol, 2022, 15(4): e122386.
22.	Kartal E, Schmidt TSB, Molina-Montes E, et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut, 2022, 71(7): 1359-1372.
23.	Chandra V, McAllister F. Therapeutic potential of microbial modulation in pancreatic cancer. Gut, 2021, 70(8): 1419-1425.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin, 2020, 70(1): 7-30.
3. Sun ZX, Shen YM, Sun ZK, et al. Survival analysis of 198 patients with pancreatic cancer in Hainan, China: A multi-institution prospective study. Asian Pac J Trop Med, 2019, 12(14): 1-13.
4. 朱鑫哲, 李浩, 徐华祥, 等. 2021年胰腺癌研究及诊疗新进展. 中国癌症杂志, 2022, 32(1): 1-12.
5. 赵思涵, 郑健. 胰腺癌病因及发病机制研究进展. 中国癌症防治杂志, 2022, 14(3): 253-263.
6. 中华医学会外科学分会胰腺外科学组. 中国胰腺癌诊治指南(2021). 中华外科杂志, 2021, 59(7): 561-577.
7. 吴白骏, 胡朝全. 胰腺癌免疫治疗的现状与进展. 实用临床医药杂志, 2022, 26(13): 134-138, 144.
8. 侯志颖. 胰腺癌危险因素及其肠道菌群多样性研究. 海口: 海南医学院, 2020.
9. 陈恬. 基于微生物组学的胰腺癌患者口腔及肠道菌群研究. 上海: 海军军医大学, 2020.
10. Flint HJ, Scott KP, Louis P, et al. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol, 2012, 9(10): 577-589.
11. 田智敏. 参苓白术散对胰腺癌营养状况的改善及胰腺癌与肠道菌群和免疫的关系研究. 上海: 上海中医药大学, 2019.
12. 邓寒丹, 范兴丽. 肠道菌群在肿瘤发生发展及免疫治疗中作用的研究进展. 生物工程学报, 2022, 38(6): 2105-2119.
13. 涂希晨. 胰腺癌患者肠道微环境的研究. 长沙: 湖南师范大学, 2020.
14. Ren Z, Jiang J, Xie H, et al. Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget, 2017, 8(56): 95176-95191.
15. Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov, 2018, 8(4): 403-416.
16. 曾宪涛, 刘慧, 陈曦, 等. Meta分析系列之四: 观察性研究的质量评价工具. 中国循证心血管医学杂志, 2012, 4(4): 297-299.
17. 陈卓, 钱祥, 张爱琴, 等. 基于肠道菌群结构特征研究胰腺癌不同中医证型与预后的相关性. 浙江中西医结合杂志, 2019, 29(12): 965-969.
18. 张德, 周文丽, 王雷, 等. 女性胰腺癌患者肠道菌群变化分析. 解放军医学院学报, 2019, 40(11): 1087-1092, 1109.
19. 谢国群, 张院辉, 郭晓冬, 等. 基于高通量测序技术的胰腺癌湿热证患者肠道菌群结构差异与功能变异研究. 上海中医药杂志, 2019, 53(12): 9-16.
20. Zhou W, Zhang D, Li Z, et al. The fecal microbiota of patients with pancreatic ductal adenocarcinoma and autoimmune pancreatitis characterized by metagenomic sequencing. J Transl Med, 2021, 19(1): 215.
21. Wang X, Sun Z, Makale EC, et al. Gut microbial profile in patients with pancreatic cancer. Jundishapur J Microbiol, 2022, 15(4): e122386.
22. Kartal E, Schmidt TSB, Molina-Montes E, et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut, 2022, 71(7): 1359-1372.
23. Chandra V, McAllister F. Therapeutic potential of microbial modulation in pancreatic cancer. Gut, 2021, 70(8): 1419-1425.

Previous Article
Screening accuracy for four common questionnaires of chronic obstructive pulmonary disease: a network meta-analysis
Next Article
The adverse reactions of piperacillin: a systematic review

Chinese Journal of Evidence-Based Medicine

The composition spectrum of intestinal bacterial diversity in Chinese pancreatic cancer patients: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content